[ February 23, 2009 ]
New York, USA
[ February 23, 2009 ]
[February 3-7, 2009]
Every 4 years, leishmaniasis experts gather together from around the world. During World Leish 4, DNDi held 2 symposia on “partnering along the path to deliver better treatments”.
[ Paris, Geneva – June 11, 2008 ]
Today, the Paris-based Institut de Recherche pour le Développement (IRD) and DNDi announced the implementation of scientific cooperation projects for developing treatments against visceral leishmaniasis, Chagas disease, and sleeping sickness.
Current Organic Chemistry, May 2008
[ February 2008 ]
The 10th Leishmaniasis East Africa Platform (LEAP) meeting took place in Khartoum, Sudan. A solid clinical trial network is being built, thanks to the serious commitment of all members. Capacity building is still ongoing, with one site in Kenya to be built and another in Uganda to be strengthened. In May 2008, DNDi and its partners inaugurated a new treatment centre in Gondar, Ethiopia, with a 24 bed capacity.
[ Geneva, Switzerland – December 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi) has received a USD 25.7 million grant from the Bill & Melinda Gates Foundation to research and develop new medicines to treat human African trypanosomiasis (HAT), also known as sleeping sickness, and visceral leishmaniasis (VL).
[ Geneva, Switzerland – November 5, 2007 ]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has granted Drugs for Neglected Diseases initiative (DNDi) USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.
[ Bangalore and Geneva – October 11, 2007 ]
Advinus Therapeutics (P) Ltd. and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organization based in Geneva, Switzerland, announced today that they have formed a collaboration for discovery and development of novel therapies for visceral leishmaniasis (kala azar), a fatal infectious disease of developing countries including India.
[ September 2007 ]
DNDi and the Leishmaniasis East Africa Platform (LEAP) organised a scientific symposium on visceral leishmaniasis (VL): “A step together in the right direction” at the centenary meeting of the Royal Society of Tropical Medicine and Hygiene (RSTMH), in London. More than 120 scientists attended the meeting.
by Alvar J, Bashaye S, Argaw D, Cruz I, Aparicio P, Kassa A, Orfanos G, Parreno F, Babaniyi O, Gudeta N, Canavate C, Bern C.
Am J Trop Med Hyg, August 2007
by Modabber F, Buffet PA, Torreele E, Milon G, Croft SL.
Kinetoplastid Biol Dis, April 2007
by Garnier T, Mantyla A, Jarvinen T, Lawrence MJ, Brown MB, Croft SL.
J Pharm Pharmacol, January 2007
by Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA.
Trans. R. Soc. Trop. Med. Hyg, 2006
by Croft SL, Engel J.
Trans R Soc Trop Med Hyg, December 2006
by Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J.
Clin Infect Dis, October 2006
[ September 2006 ]
Over 200 African scientists from 34 countries met in Nairobi, Kenya, 19-23 September at an international conference organised by the Drugs for Neglected Diseases initiative (DNDi), to explore developing greater regional research partnerships to combat the most neglected diseases, such as sleeping sickness, kala azar and malaria.
by Garnier T, Brown MB, Lawrence MJ, Croft SL.
J Pharm Pharmacol, August 2006
by Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F.
Drug Resist Updates, Feb-Apr 2006
by Croft SL, Seifert K, Yardley V.
Indian J Med Res, March 2006
by Croft SL, Sundar S, Fairlamb AH.
Clin Microbiol Rev, January 2006